IO Biotech Company Insiders

IOBT Stock  USD 0.52  0.01  1.96%   
IO Biotech employs about 80 people. The company is managed by 20 executives with a total tenure of roughly 187 years, averaging almost 9.0 years of service per executive, having 4.0 employees per reported executive. Breaking down IO Biotech's management performance can provide insight into the firm performance.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IO Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.

IO Biotech Management Team Effectiveness

The company has return on total asset (ROA) of (0.8858) % which means that it has lost $0.8858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4048) %, meaning that it created substantial loss on money invested by shareholders. IO Biotech's management efficiency ratios could be used to measure how well IO Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
IO Biotech secures a total of 71.95 Million outstanding shares. 30% of IO Biotech outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.

IO Biotech Workforce Comparison

IO Biotech is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 658. IO Biotech retains roughly 80.0 in number of employees claiming about 12% of equities under Health Care industry.

IO Biotech Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IO Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on IO Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, IO Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

IO Biotech Notable Stakeholders

An IO Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IO Biotech often face trade-offs trying to please all of them. IO Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IO Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pr MDCoFounder AdvisorProfile
MaiBritt ZoccaPresident, FounderProfile
Qasim MDChief OfficerProfile
Faical MiyaraChief OfficerProfile
Brian CPASenior OfficerProfile
Amy SullivanChief OfficerProfile
Anders LjungqvistFounderProfile
Brian BurkavageChief OfficerProfile
Pr AndersenFounder AdvisorProfile
Eva MDChief OfficerProfile
Pr StratenFounderProfile
Devin SmithGeneral SecretaryProfile
Daniel MannixSenior AffairsProfile
Eric MBAChief OfficerProfile
Muhammad AlHajjChief OfficerProfile
Mikkel DybkjrVP FinProfile
Amy MBAChief OfficerProfile
Devin JDGeneral SecretaryProfile
Marjan PharmDSenior LeadProfile
Diane McDowellSenior AffairsProfile
String symbol = request.getParameter("s");

About IO Biotech Management Performance

The success or failure of an entity such as IO Biotech often depends on how effective the management is. IO Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IOBT management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IOBT management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.
Please note, the imprecision that can be found in IO Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IO Biotech. Check IO Biotech's Beneish M Score to see the likelihood of IO Biotech's management manipulating its earnings.

IO Biotech Workforce Analysis

Traditionally, organizations such as IO Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IO Biotech within its industry.

IO Biotech Manpower Efficiency

Return on IO Biotech Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.2M
Net Loss Per Executive4.8M
Working Capital Per Employee568.3K
Working Capital Per Executive2.3M

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.